A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology

Overview of attention for article published in Reproductive Biology and Endocrinology, January 2014

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 25 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study

Article in Gynecologic and Obstetric Investigation (June 2023)

Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation

Article in Best Practice & Research Clinical Obstetrics & Gynaecology (February 2022)

Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007–2017)

Article in Reproductive Biology and Endocrinology (May 2021)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.